drugset / Trial / NCT00557713
XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
Phase 2
Unknown
44 enrolled
Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials
Hoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.
Timeline
- Start
- 2007-02
- Primary completion
- —
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |